Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated…

Continue ReadingQureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

Combat Medical (Combat), a medical device company optimising the delivery and efficacy of cancer therapeutics, today announced new real-world data showing 68% high-grade recurrence-free survival (HG-RFS) at 12 months in…

Continue ReadingCombat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study